Compugen Ltd. (CGEN)

3.21
0.09 2.70
NASDAQ : Health Technology
Prev Close 3.30
Open 3.25
Day Low/High 3.17 / 3.31
52 Wk Low/High 2.35 / 5.00
Volume 118.13K
Avg Volume 206.80K
Exchange NASDAQ
Shares Outstanding 57.12M
Market Cap 197.64M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Compugen Third Quarter 2018 Conference Call Scheduled For Wednesday, November 7, 2018 At 8:30 AM ET

Compugen Third Quarter 2018 Conference Call Scheduled For Wednesday, November 7, 2018 At 8:30 AM ET

HOLON, Israel, Oct. 24, 2018 /PRNewswire/ --  Compugen Ltd.

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

NEW YORK and HOLON, Israel, Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in...

Compugen Announces First Patient Dosed With COM701, A First-in-Class Cancer Immunotherapy Antibody, In Phase 1 Clinical Trial

Compugen Announces First Patient Dosed With COM701, A First-in-Class Cancer Immunotherapy Antibody, In Phase 1 Clinical Trial

Phase 1 study will assess COM701 both as a single agent and in combination with an anti-PD‑1 antibody in patients with advanced solid tumors

Compugen Announces Appointment Of Dr. Jean-Pierre Bizzari To Its Board Of Directors

Compugen Announces Appointment Of Dr. Jean-Pierre Bizzari To Its Board Of Directors

HOLON, Israel, Sept. 5, 2018 /PRNewswire/ -- Compugen Ltd.

Compugen Reports Second Quarter 2018 Results

Compugen Reports Second Quarter 2018 Results

Preparations for first patient dosing on track to take place in early fall

Compugen Second Quarter 2018 Conference Call Scheduled For Wednesday, August 1, 2018 At 8:30 AM ET

Compugen Second Quarter 2018 Conference Call Scheduled For Wednesday, August 1, 2018 At 8:30 AM ET

HOLON, Israel, July 18, 2018 /PRNewswire/ --  Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2018 financial results...

Compugen Welcomes FDA Clearance Of Bayer's IND Application For BAY 1905254

Compugen Welcomes FDA Clearance Of Bayer's IND Application For BAY 1905254

First-in-class therapeutic antibody targets ILDR2, a novel immune checkpoint discovered by Compugen

Compugen Announces FDA Clearance Of IND Application For COM701, A First-in-class Immuno-Oncology Therapeutic Antibody

Compugen Announces FDA Clearance Of IND Application For COM701, A First-in-class Immuno-Oncology Therapeutic Antibody

A Phase 1 trial in patients with advanced solid tumors is to be conducted at multiple centers in the United States

Compugen Announces $21 Million Registered Direct Offering Of Ordinary Shares And Warrants

Compugen Announces $21 Million Registered Direct Offering Of Ordinary Shares And Warrants

HOLON, Israel, June 15, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN)(CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has entered into a definitive securities purchase agreement...

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Compugen Enters Oversold Territory

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen is Now Oversold (CGEN)

Compugen is Now Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Compugen (CGEN)

Oversold Conditions For Compugen (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Enters Oversold Territory (CGEN)

Compugen Enters Oversold Territory (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.

Compugen Becomes Oversold (CGEN)

Compugen Becomes Oversold (CGEN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Compugen

Relative Strength Alert For Compugen

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare...

Stocks to Watch for 2016 M&A Deals

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen To Present At The Oppenheimer Healthcare Conference In New York

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual...

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen To Present At Jefferies 2015 Global Healthcare Conference In London

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Dr.

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. Reports 3rd Quarter 2015 Financial Results

Compugen Ltd. ( NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the third quarter ending September 30, 2015.

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Third Quarter 2015 Conference Call Scheduled For Tuesday, November 3, 2015 At 10:00 AM ET

Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, November 3, 2015 to review third quarter 2015 results.

TheStreet Quant Rating: D (Sell)